BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

...a time when the tumor burden and suppressive immune cells are low. DCprime’s lead asset, DCP-001...
...a shift of the DCOne myelogenous leukemic cell line into a mature dendritic cell phenotype. DCP-001...
BioCentury | Aug 24, 2015
Company News

Eisai sales and marketing update

...Eisai’s Eidia Co. Ltd. subsidiary launched Stacia Cleia Pivka-II in Japan with an automated immunoanalyzer from...
...to measure hepatocellular carcinoma (HCC) marker prothrombin induced in vitamin K absence-II ( PIVKA-II ; DCP...
BioCentury | Jun 17, 2013
Clinical News

DCP-001: Phase I/II data

...DCP-001 given every 2 weeks for 4 vaccinations was safe and well tolerated. DCPrime said DCP-001...
...trial, but declined to disclose a time frame. DCPrime B.V. , Amsterdam, the Netherlands Product: DCP-001...
BioCentury | Jul 2, 2012
Clinical News

DCP-001 regulatory update

...The European Commission granted Orphan Drug designation for DCPrime's DCP-001 to treat acute myelogenous leukemia (AML...
...is in Phase I/IIa testing for the indication. DCPrime B.V. , Amsterdam, the Netherlands Product: DCP-001...
BioCentury | Jun 18, 2012
Product Development

Immune springboard

...with acute myelogenous leukemia (AML) and thus expresses multiple AML-specific antigens. The company's lead product, DCP-001...
...chemotherapy is able to produce," said Zwaal. DCPrime has begun a Phase I/IIa trial of DCP-001...
...start a randomized Phase II trial in 80-100 AML patients in mid-2013. A second product, DCP-002...
BioCentury | Feb 6, 2012
Clinical News

DCP-001 regulatory update

...EMA's CHMP issued a positive opinion to grant Orphan Drug designation for DCPrime's DCP-001 to treat...
...is in Phase I/IIa testing for the indication. DCPrime B.V. , Amsterdam, the Netherlands Product: DCP-001...
BioCentury | May 2, 2011
Clinical News

DCP-001: Phase I started

...trial to evaluate DCP-001 in 12 AML patients. DCPrime B.V. , Amsterdam, the Netherlands Product: DCP-001...
BioCentury | Mar 7, 2011
Clinical News

UTASWako i30 regulatory update

...uTASWako i30 automated instrument for use with its FDA-cleared alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP...
Items per page:
1 - 8 of 8